All In Biotech

NDA 218771 · Almaject

Teriparatide

Teriparatide · Subcutaneous

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 4, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

155

34 Phase 3, 5 recruiting

FAERS reports

7,158

4,980 serious, 406 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 4, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • TERIPARATIDE · TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Teriparatide" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness525
  • nausea523
  • fall503
  • fatigue487
  • back pain474
  • arthralgia461
  • device malfunction451
  • product dose omission issue433
  • pain in extremity425
  • pain397
  • headache391
  • device operational issue360

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200533
200616
200757
200840
200952
201044
201185
2012307
2013509
2014150
2015142
2016129
2017310
2018437
2019492
2020228
2021185
2022299
2023476
2024986
20251,380
2026791

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Teriparatide (Teriparatide)

2024 spending

$213M

Beneficiaries

15,831

81,093 claims

Per beneficiary

$13,431

$962.44 per unit

View as table
YearSpending
2020$956,570
2021$24,618,813
2022$62,447,673
2023$89,084,656
2024$212,620,906

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 489 on PubMed

Sponsor: Almaject

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.